Hans-Ulrich Demuth
No más puestos en curso
Perfil
Hans-Ulrich Demuth was the founder of Vivoryon Therapeutics NV, which was founded in 1997, where he held the title of Chief Scientific Officer from 2009 to 2013.
He was also a Co-Managing Director at Ingenium Pharmaceuticals GmbH in 2012.
In addition, he was a Principal at Hochschule Anhalt and a Mitglied at Martin-Luther-Universität Halle-Wittenberg.
Dr. Demuth received his undergraduate degree from Martin-Luther-Universität Halle-Wittenberg.
Antiguos cargos conocidos de Hans-Ulrich Demuth.
Empresas | Cargo | Fin |
---|---|---|
VIVORYON THERAPEUTICS N.V. | Fundador | 31/01/2013 |
Hochschule Anhalt | Corporate Officer/Principal | - |
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Director Ejecutivo | - |
Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
Formación de Hans-Ulrich Demuth.
Martin-Luther-Universität Halle-Wittenberg | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
VIVORYON THERAPEUTICS N.V. | Health Technology |
Empresas privadas | 1 |
---|---|
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
- Bolsa de valores
- Insiders
- Hans-Ulrich Demuth